Madrigal Pharmaceuticals (MDGL) Earnings Date & Reports

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality... Show more

Industry: #Pharmaceuticals Other

Get AI intraday signals

A.I. Advisor

published Earnings

MDGL is expected to report earnings to fall 27.38% to -235 cents per share on August 11

Madrigal Pharmaceuticals MDGL Stock Earnings Reports

Q2'26

Est.

$-2.36

Q1'26

Beat

by $0.94

Q4'25

Missed

by $1.97

Q3'25

Missed

by $3.11

Q2'25

Beat

by $1.73

The last earnings report on May 06 showed earnings per share of -325 cents, beating the estimate of -419 cents. With 187.09K shares outstanding, the current market capitalization sits at 11.24B.

View a ticker or compare two or three

Compare

MDGL

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for MDGL